logo
ResearchBunny Logo
Breast Cancer Screening Using Clinical Breast Examination: A Cost-Effectiveness Analysis for South Africa

Medicine and Health

Breast Cancer Screening Using Clinical Breast Examination: A Cost-Effectiveness Analysis for South Africa

S. D. Masuku, O. Mandrik, et al.

WHO emphasizes screening to reduce advanced cancer; South Africa recommends twice-yearly clinical breast examinations (CBEs) for women 40–69. This study conducted by Sithabiso D. Masuku, Olena Mandrik, Noreen D. Mdege, Gauravi Mishra, Richard Muwonge, Gesine Meyer-Rath, Naomi Lince-Deroche, and Alan Brennan models scaling CBE coverage from 5% to 25% and 75%, finding modest mortality reductions (0.7% and 2.3%), DALYs averted, and cost-per-DALY estimates—and concludes life-years are saved but not cost-effective under the $3,015 threshold.

00:00
00:00
~3 min • Beginner • English
Abstract
Objectives: The World Health Organization emphasizes screening and early diagnosis to reduce advanced cancer incidence and mortality. In low-to-middle-income countries, breast cancer survival rates are low because of late detection. South Africa's policy recommends twice-yearly clinical breast examinations (CBEs) for asymptomatic women aged 40 to 69. We assessed the impact of scaling up CBE screening on mortality and cost-effectiveness. Methods: Using trial data on downstaging, we compared the current baseline (5% coverage) with scenario 1 (25% coverage by year 5 [ie, 5% increase annually]) and scenario 2 (75% coverage by year 5, [ie, 17.5% increase annually]). A cohort model tracked women from screening to diagnosis, estimating downstaging's impact on breast cancer cases over their lifetime. Costs from the healthcare payer's perspective are presented in 2022 US dollars. Results: Five-year screen detection rates were 2.39 and 2.08 per 1000 women screened for scenarios 1 and 2, respectively. Scenario 1 reduced breast cancer mortality by 0.7% and scenario 2 by 2.3%. Compared with no screening, the current baseline screening program averts 1645 disability-adjusted life years (DALYs) at $20,341/DALY averted. Scenario 1 averted 3823 DALYs with economic efficiency improving to $17,776/DALY averted, whereas scenario 2 averted 12,165 DALYs at $19,552/DALY averted. Conclusions: CBE scale-up effectively saves life years but is not cost-effective under the country's opportunity cost-derived threshold of $3,015/DALY averted. However, decisions on the best screening policy are not solely based on cost-effectiveness. They involve careful consideration of budgetary constraints and competing healthcare priorities. Scale-up should consider system capacity, minimum care standards and cost-effective early detection strategies.
Publisher
Value in Health Regional Issues
Published On
Authors
Sithabiso D. Masuku, Olena Mandrik, Noreen D. Mdege, Gauravi Mishra, Richard Muwonge, Gesine Meyer-Rath, Naomi Lince-Deroche, Alan Brennan
Tags
Clinical breast examination
Downstaging
Cost-effectiveness
Breast cancer screening
Disability-adjusted life years (DALYs)
South Africa
Screening coverage scenarios
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny